Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Open-market buy CEO, Pres, CFO, Treas & Secy bought 25,000 shares at $0.90 ($22,380)
  4. 4 Open-market buy Director bought 5,983 shares at $0.80 ($4,786)
  5. 4 Grant or award Director acquired 4,288,624 shares (grant or award)
  6. 4 Open-market buy Director bought 19,390 shares at an average $0.75 ($14,560)
  7. 4 Open-market buy Director bought 32,112 shares at an average $0.71 ($22,691)
  8. 4 Open-market buy Director bought 13,015 shares at an average $0.68 ($8,828)
  9. 4 Open-market buy Director bought 3,100 shares at an average $0.69 ($2,131)
  10. 4 Open-market buy Director bought 8,000 shares at $0.68 ($5,440)
  11. 4 Open-market buy Director bought 6,665 shares at an average $0.71 ($4,709)
  12. 4 Open-market buy Director bought 8,845 shares at an average $0.71 ($6,275)
  13. 4 Open-market buy Director bought 17,781 shares at an average $0.62 ($11,082)
  14. 4 Open-market buy Director bought 17,189 shares at $0.59 ($10,142)
  15. 4 Grant or award Director acquired 4,288,624 shares (grant or award)
  16. 4 Derivatives Options or other derivatives
  17. 4/A Derivatives Options or other derivatives
  18. 4 Open-market buy Director bought 18,354 shares at an average $0.53 ($9,651)
  19. 4 Open-market buy Director bought 4,713 shares at an average $0.65 ($3,075)
  20. 4 Open-market buy Director bought 15,000 shares at $0.68 ($10,251)

Page 11 of 16 · 305 filings